Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2

Summary

Human parvovirus B19 (B19) DNA has frequently been detected in plasma-derived coagulation factor concentrates. Furthermore, transmission of B19 infection was observed, indicating presence of the infectious virus despite routine viral inactivation/removal procedures during the manufacturing process. Recently, human parvovirus DNA isolates, variant from B19, have been identified resulting in classification of B19 virus into three distinct genotypes, with all viruses previously classified as B19 belonging to genotype 1. So far, there is no information available on contamination of clotting factor concentrates with genotype 2. Therefore, we analysed 202 different factor concentrate lots for genotype 1 and 2 DNA by PCR. Analysis of one hundred eighty-one lots representing 13 different products, administered over the last three years, was compared to 21 lots (8 products) used until the early 1980s which had not been treated by viral inactivation procedures. Genotype 1 DNA was detected in 77/181 (42.5%) currently administered lots, and 17/21 (81%) previously used lots. The level of genotype 1 DNA contamination was similar in currently and previously administered concentrates. Genotype 2 DNA was found in 5/202 (2.5%) lots, all of which were co-contaminated with genotype 1 DNA. DNA sequence analysis showed that the PCR-double positive concentrates contained typical genotype 1 and genotype 2 DNA. Because genotype 2 appears to cause a similar spectrum of diseases as genotype 1, simultaneous detection of genotype 2 by nucleic acid amplification testing (NAT), now widely applied to plasma pools for genotype 1, would give an added level of safety to blood products.

Keywords

Human parvovirus - genotype 2 - coagulation factor concentrates

• References

• 1 Zakrzewska K, Azzi A, Patou G. et al. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 1992; 81: 407-12.
• 2 Lefrère JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated antihaemophilia concentrates. Lancet 1994; 343: 211-2.
• 3 Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93: 714-9.
• 4 Eis-Hübinger AM, Sasowski U, Brackmann HH. Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost 1999; 81: 476-7.
• 5 Schmidt I, Blümel J, Seitz H. et al. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001; 81: 228-35.
• 6 Bartolomei OCorsi, Azzi A, Morfini M. et al. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 1988; 25: 165-70.
• 7 Lyon DJ, Chapman CS, Martin C. et al. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; 01: 1085.
• 8 Yee TT, Cohen BJ, Pasi KJ. et al. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 457-9.
• 9 Santagostino E, Mannucci PM, Gringeri A. et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization. Transfusion 1997; 37: 517-22.
• 10 Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204.
• 11 Hino M, Ishiko O, Honda KI. et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol 2000; 108: 194-5.
• 12 Blümel J, Schmidt I, Effenberger W. et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002; 42: 1473-81.
• 13 Nguyen QT, Sifer C, Schneider V. et al. Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia. Lancet 1998; 352: 1524.
• 14 Hokynar K, Söderlund-Venermo M, Pesonen M. et al. A new parvovirus genotype persistent in human skin. Virology 2002; 302: 224-8.
• 15 Servant A, Laperche S, Lallemand F. et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76: 9124-34.
• 16 Gallinella G, Venturoli S, Manaresi E. et al. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol 2003; 28: 1-13.
• 17 Nguyen QT, Wong S, Heegaard ED. et al. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002; 301: 374-80.
• 18 Schneider B, Reber U, Tolba R. et al. Prevalence of human parvovirus genotype 1 and genotype 2 DNA in livers and bone marrows of adults. Annual Meeting of GfV – Joint Meeting with SIV, March 17-20, Tübingen, Germany..
• 19 Eis-Hübinger AM, Sasowski U, Brackmann HH. et al. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost 1996; 76: 1120.
• 20 Hemauer A, von Poblotzki A, Gigler A. et al. Sequence variability among different parvovirus B19 isolates. J Gen Virol 1996; 77: 1781-5.
• 21 Shade RO, Blundell MC, Cotmore SF. et al. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986; 58: 921-36.
• 22 Saldanha J, Lelie N, Yu MW. et al. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002; 82: 24-31.
• 23 Wong S, Young NS, Brown KE. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associat-ed aplastic anemia. J Infect Dis 2003; 187: 1581-6.
• 24 Söderlund M, von Essen R, Haapasaari J. et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349: 1063-5.
• 25 Cassinotti P, Burtonboy G, Fopp M. et al. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53: 229-32.
• 26 Eis-Hübinger AM, Reber U, Abdul-Nour T. et al. Evidence for persistence of parvovirus B19 DNA in livers of adults. J Med Virol 2001; 65: 395-401.
• 27 Musiani M, Zerbini M, Gentilomi G. et al. Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis 1995; 172: 1360-3.
• 28 Ozawa K, Kurtzman G, Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986; 233: 883-6.
• 29 Srivastava A, Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J Virol 1988; 62: 3059-63.
• 30 Munshi NC, Zhou S, Woody MJ. et al. Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol 1993; 67: 562-6.
• 31 Blümel J, Schmidt I, Willkommen H. et al. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42: 1011-8.
• 32 Yunoki M, Tsujikawa M, Urayama T. et al. Heat sensitivity of human parvovirus B19. Vox Sang 2003; 84: 164-9.
• 33 Aubin JT, Defer C, Vidaud M. et al. Largescale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang 2000; 78: 7-12.
• 34 Cohen BJ, Field AM, Gudnadottir S. et al. Blood donor screening for parvovirus B19. J Virol Methods 1990; 30: 233-8.
• 35 Brown KE, Young NS, Alving BM. et al. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41: 130-5.